AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21149764 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study 21149764 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21150563 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 400 mg once daily
Number of subjects: 157
Study 21150563 — intervention group
Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily
Number of subjects: 157
Study 21150709 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component mRNA-based tumor vaccine (free and protamine-complexed mRNA)
Number of subjects: 0
Study 21150709 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component mRNA-based tumor vaccine
Number of subjects: 0
Study 21150884 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele of rs1656930
Number of subjects: 3297
Study 21150884 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor alleles of rs1656930 and rs9882205
Number of subjects: 3297
Study 21150884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ile164Thr genotype
Number of subjects: 3297
Study 21150884 — intervention group
Group type: EXPERIMENTAL
Intervention: Common variant of ADIPOQ (minor allele of rs1656930)
Number of subjects: 3297
Study 21155613 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) 100 μg, administered once daily as a subcutaneous injection for 12 months
Number of subjects: 112
Study 21155613 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 112
Study 21155708 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Number of subjects: 1012
Study 21156020 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 102 at 10 mg/kg
Number of subjects: 61
Study 21156020 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 102 at 20 mg/kg
Number of subjects: 61
Study 21156020 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 102 (both doses)
Number of subjects: 61
Study 21156071 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30-70 mg/d
Number of subjects: 129
Study 21156071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 21159707 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) confirmed in patients with VTE
Number of subjects: 840
Study 21159707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OSA)
Number of subjects: 840
Study 21159788 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary vitamin E intake
Number of subjects: 19
Study 21159788 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood α-CEHC and γ-CEHC concentrations
Number of subjects: 19
Study 21159788 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal α-tocopherol:total lipids ratios
Number of subjects: 19
Study 21159788 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite:tocopherol ratios in cord blood
Number of subjects: 19
Study 21159841 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg sc every 6 months
Number of subjects: 200
Study 21160068 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dicer expression in symptomatic myeloma patients
Number of subjects: 151
Study 21160068 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal gammopathy of undetermined significance
Number of subjects: 151
Study 21163497 — intervention group
Group type: EXPERIMENTAL
Intervention: Single patch repair
Number of subjects: 120
Study 21163497 — intervention group
Group type: EXPERIMENTAL
Intervention: Double patch repair
Number of subjects: 120
Study 21163497 — intervention group
Group type: EXPERIMENTAL
Intervention: Single atrial septal defect patch with primary ventricular septal defect closure
Number of subjects: 120
Study 21163497 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 120
Study 21163497 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at surgery
Number of subjects: 120
Study 21163927 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (lenograstim, 263 μg)
Number of subjects: 168
Study 21164752 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive complex diffusion despeckling filter
Number of subjects: 0
Study 21164752 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic data
Number of subjects: 0
Study 21167034 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced feedback group (receives performance feedback reports and a theory-informed worksheet)
Number of subjects: 0
Study 21167034 — intervention group
Group type: COMPARATOR
Intervention: Simple feedback group (receives performance feedback reports every six months for two years)
Number of subjects: 0
Study 21167034 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced feedback group
Number of subjects: 0
Study 21167116 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent seasonal influenza vaccine (15μg of hemagglutinin of each virus strain)
Number of subjects: 142
Study 21167116 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent seasonal influenza vaccine
Number of subjects: 142
Study 21168023 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 3075
Study 21168023 — intervention group
Group type: COMPARATOR
Intervention: Registry patients undergoing CABG
Number of subjects: 3075
Study 21168813 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft insertion with the EndoGlide
Number of subjects: 25
Study 21168818 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1B1 mutations
Number of subjects: 34
Study 21168818 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1B1 and MYOC mutations
Number of subjects: 34
Study 21169806 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 167
Study 21169856 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (40, 80, or 120 mg daily for up to 5 years)
Number of subjects: 116
Study 21170669 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 175 mg PO daily in combination with gemcitabine (1000 mg/m(2))
Number of subjects: 34
Study 21170669 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (implied control)
Number of subjects: 34
Study 21170901 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering colorectal cancer screening (CRCS) at the time of mammography without a physician's referral.
Number of subjects: 611
Study 21170955 — intervention group
Group type: EXPERIMENTAL
Intervention: Melancholic MDD participants
Number of subjects: 29
Study 21170955 — intervention group
Group type: COMPARATOR
Intervention: Nonmelancholic MDD participants
Number of subjects: 29
Study 21170955 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 29
Study 21172791 — intervention group
Group type: COMPARATOR
Intervention: 400/100 mg lopinavir/ritonavir twice daily
Number of subjects: 22
Study 21172791 — intervention group
Group type: EXPERIMENTAL
Intervention: 200/150 mg lopinavir/ritonavir twice daily
Number of subjects: 22
Study 21172791 — intervention group
Group type: EXPERIMENTAL
Intervention: 200/50 mg lopinavir/ritonavir twice daily
Number of subjects: 22
Study 21173002 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 1869
Study 21173002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1869
Study 21173095 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous veltuzumab 80 mg
Number of subjects: 17
Study 21173095 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous veltuzumab 160 mg
Number of subjects: 17
Study 21173095 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous veltuzumab 320 mg
Number of subjects: 17
Study 21173095 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous veltuzumab (all doses combined)
Number of subjects: 17
Study 21173101 — intervention group
Group type: EXPERIMENTAL
Intervention: FBS0701, a novel oral iron chelator, given daily for 7 days at doses up to 32 mg/kg
Number of subjects: 16
Study 21173101 — intervention group
Group type: EXPERIMENTAL
Intervention: FBS0701, a novel oral iron chelator
Number of subjects: 16
Study 21173499 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 7090
Study 21173499 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 7090
Study 21173649 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants not meeting American Cancer Society guidelines for physical activity (150 min/wk)
Number of subjects: 120
Study 21173653 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous minor allele at TNF-α -308
Number of subjects: 834
Study 21173653 — intervention group
Group type: COMPARATOR
Intervention: Heterozygous or homozygous major allele at TNF-α -308
Number of subjects: 834
Study 21173653 — intervention group
Group type: COMPARATOR
Intervention: IL-6 -174 and IL-1β +3954 SNP
Number of subjects: 834
Study 21173699 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucin balls presence (single episode)
Number of subjects: 205
Study 21173699 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucin balls presence (repeated episodes)
Number of subjects: 205
Study 21173699 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated presence of mucin balls
Number of subjects: 205
Study 21174485 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG)
Number of subjects: 976
Study 21174485 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 976
Study 21174506 — intervention group
Group type: EXPERIMENTAL
Intervention: Varespladib methyl
Number of subjects: 0
Study 21174506 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care with atorvastatin 80 mg
Number of subjects: 0
Study 21176217 — intervention group
Group type: COMPARATOR
Intervention: AUD patients
Number of subjects: 40
Study 21176218 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-20 ml/kg of 4°C cold normal saline (TH group)
Number of subjects: 40
Study 21176218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-hospital cooling)
Number of subjects: 40
Study 21176218 — intervention group
Group type: EXPERIMENTAL
Intervention: TH group with 17 ml/kg of cold saline
Number of subjects: 40
Study 21176218 — intervention group
Group type: EXPERIMENTAL
Intervention: TH group
Number of subjects: 40
Study 21176218 — intervention group
Group type: EXPERIMENTAL
Intervention: TH group with in-hospital continuation of cooling
Number of subjects: 40
Study 21176752 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg administered after HD during a 48 h - 48 h - 72 h dialysis week.
Number of subjects: 16
Study 21176752 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg administered before a CAPD dwell time over a 48 h - 48 h - 48 h dialysis week.
Number of subjects: 16
Study 21177735 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding associated transmission in mothers who tested HIV positive at baseline (n=2870)
Number of subjects: 14110
Study 21177735 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding associated transmission in mothers who seroconverted postnatally (n=334)
Number of subjects: 14110
Study 21177735 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding associated transmission in mothers who seroconverted postnatally with known timing of infection (n=51)
Number of subjects: 14110
Study 21177735 — intervention group
Group type: EXPERIMENTAL
Intervention: Median plasma HIV concentration in mothers who seroconverted postnatally
Number of subjects: 14110
Study 21177735 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk HIV load in mothers who seroconverted postnatally
Number of subjects: 14110
Study 21177735 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of women whose plasma sample tested negative for HIV with ELISA but positive with PCR (n=17)
Number of subjects: 14110
Study 21177735 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall breastfeeding associated transmission in the ZVITAMBO trial
Number of subjects: 14110
Study 21177912 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB (3 doses at baseline, 2 months, and 6 months)
Number of subjects: 54
Study 21177912 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (1 dose 1 month after 4CMenB)
Number of subjects: 54
Study 21177912 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-CRM
Number of subjects: 54
Study 21178246 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-load treadmill tests at 3.2 km/h, 10% grade.
Number of subjects: 777
Study 21178246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-correlation analysis for intra-test and test-retest reproducibility.
Number of subjects: 777
Study 21178394 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel synthetic TB subunit vaccine
Number of subjects: 0
Study 21178655 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg famciclovir
Number of subjects: 53
Study 21178824 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury (AKI)
Number of subjects: 229
Study 21178824 — intervention group
Group type: COMPARATOR
Intervention: No acute kidney injury (non-AKI)
Number of subjects: 229
Study 21179201 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU/d vitamin D3 for 12 weeks
Number of subjects: 15
Study 21179892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel–nitrilotriacetic acid (Ni–NTA) affinity chromatography
Number of subjects: 11
Study 21180274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus treatment after 101-200 days (n = 6)
Number of subjects: 38
Study 21180274 — intervention group
Group type: COMPARATOR
Intervention: SGRQ scores
Number of subjects: 38
Study 21183651 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1561
Study 21183651 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 1561
Study 21184871 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchoring flap (AF)
Number of subjects: 43
Study 21184871 — intervention group
Group type: COMPARATOR
Intervention: Flared end (FE)
Number of subjects: 43
Study 21184871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 21185022 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle mitochondrial function measured by phosphocreatine recovery (τPCr) after sub-maximal exercise
Number of subjects: 40
Study 21185022 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle mitochondrial function (τPCr)
Number of subjects: 40
Study 21186011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM)
Number of subjects: 220
Study 21187495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with CEA-derived HLA-A2 binding peptide
Number of subjects: 16
Study 21187495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells transfected with CEA mRNA
Number of subjects: 16
Study 21187495 — intervention group
Group type: COMPARATOR
Intervention: Control protein (KLH)
Number of subjects: 16
Study 21188121 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol/GP (80 g of grape powder per day)
Number of subjects: 8
Study 21188121 — intervention group
Group type: COMPARATOR
Intervention: Control (normal colonic mucosa and colon cancer tissue pre-exposure)
Number of subjects: 8
Study 21190974 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk for thyroid disease
Number of subjects: 4394
Study 21190974 — intervention group
Group type: COMPARATOR
Intervention: Low risk for thyroid disease
Number of subjects: 4394
Study 21190974 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PPT
Number of subjects: 4394
Study 21191140 — intervention group
Group type: COMPARATOR
Intervention: Highest quintile of fish consumption (>3.0 servings of fish/wk)
Number of subjects: 34670
Study 21191140 — intervention group
Group type: COMPARATOR
Intervention: ≥3 servings of lean fish/wk
Number of subjects: 34670
Study 21191530 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable risperidone long-acting therapy (25-50mg, injected every 2 weeks)
Number of subjects: 355
Study 21191530 — intervention group
Group type: COMPARATOR
Intervention: Oral aripiprazole (5-30mg/day)
Number of subjects: 355
Study 21193540 — intervention group
Group type: EXPERIMENTAL
Intervention: Room light exposure before bedtime
Number of subjects: 116
Study 21193540 — intervention group
Group type: COMPARATOR
Intervention: Dim light exposure before bedtime
Number of subjects: 116
Study 21193540 — intervention group
Group type: EXPERIMENTAL
Intervention: Room light exposure during usual hours of sleep
Number of subjects: 116
Study 21193691 — intervention group
Group type: EXPERIMENTAL
Intervention: I-123 metaiodobenzylguanidine imaging with late H/M ratio <1.6 in diabetic subjects
Number of subjects: 961
Study 21193691 — intervention group
Group type: COMPARATOR
Intervention: I-123 metaiodobenzylguanidine imaging with late H/M ratio ≥1.6 in diabetic subjects
Number of subjects: 961
Study 21193691 — intervention group
Group type: EXPERIMENTAL
Intervention: I-123 metaiodobenzylguanidine imaging parameters
Number of subjects: 961
Study 21194015 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock Drawing Test (CDT) administered at all time points
Number of subjects: 83
Study 21194015 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock Drawing Test (CDT)
Number of subjects: 83
Study 21194419 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium control-target of 4.0 mmol/L
Number of subjects: 1200
Study 21194419 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium control-target of 4.5 mmol/L
Number of subjects: 1200
Study 21195036 — intervention group
Group type: EXPERIMENTAL
Intervention: Desaturators (SpO(2)<90% for ≥30% recording time)
Number of subjects: 60
Study 21195036 — intervention group
Group type: COMPARATOR
Intervention: Non-desaturators (SpO(2)≥90%)
Number of subjects: 60
Study 21195518 — intervention group
Group type: EXPERIMENTAL
Intervention: Early renal service involvement (EARLI), defined as a 1-time nephrology consultation within 18 hours of the onset of AKI.
Number of subjects: 176
Study 21195518 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 176
Study 21195518 — intervention group
Group type: EXPERIMENTAL
Intervention: EARLI intervention group.
Number of subjects: 176
Study 21196729 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlarged basilar artery diameters (BADs) in FD patients
Number of subjects: 71
Study 21198359 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year lifestyle intervention
Number of subjects: 51
Study 21199970 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion
Number of subjects: 44
Study 21199970 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted transfusion
Number of subjects: 44
Study 21199970 — intervention group
Group type: COMPARATOR
Intervention: Control group (full-term healthy children)
Number of subjects: 44
Study 21200021 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon α (IFNα) treatment
Number of subjects: 0
Study 21200021 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection of the thymus
Number of subjects: 0
Study 21200021 — intervention group
Group type: EXPERIMENTAL
Intervention: MHC-I up-regulation
Number of subjects: 0
Study 21203546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-HIV vaccination
Number of subjects: 100
Study 21203574 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facility deliveries
Number of subjects: 22243
Study 21203574 — intervention group
Group type: COMPARATOR
Intervention: Non-facility deliveries at home
Number of subjects: 22243
Study 21203574 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled attendants
Number of subjects: 22243
Study 21203574 — intervention group
Group type: EXPERIMENTAL
Intervention: Drying the baby
Number of subjects: 22243
Study 21203574 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrapping the baby
Number of subjects: 22243
Study 21203574 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparations for delivery
Number of subjects: 22243
Study 21203574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord cutting practices
Number of subjects: 22243
Study 21203574 — intervention group
Group type: COMPARATOR
Intervention: Dipping in cold water
Number of subjects: 22243
Study 21203574 — intervention group
Group type: COMPARATOR
Intervention: Bathing within 6 hours
Number of subjects: 22243
Study 21203574 — intervention group
Group type: COMPARATOR
Intervention: Putting something on the cord
Number of subjects: 22243
Study 21203574 — intervention group
Group type: COMPARATOR
Intervention: Skin-to-skin contact
Number of subjects: 22243
Study 21203574 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding within 24 hours
Number of subjects: 22243
Study 21203574 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding within 1 hour
Number of subjects: 22243
Study 21203574 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastfeeding in the first 3 days
Number of subjects: 22243
Study 21204803 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 134
Study 21204803 — intervention group
Group type: COMPARATOR
Intervention: No Colonoscopy
Number of subjects: 134
Study 21205021 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin stimulation in type 1 diabetic patients
Number of subjects: 8
Study 21205057 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2a and weight-based ribavirin for 24 weeks (genotype non-1)
Number of subjects: 53
Study 21205057 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2a and weight-based ribavirin for 48 weeks (genotype 1)
Number of subjects: 53
Study 21205057 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2a and weight-based ribavirin
Number of subjects: 53
Study 21205715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 0
Study 21205715 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21206909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg p.o. twice daily continuously
Number of subjects: 36
Study 21207052 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 350
Study 21207052 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with anterior uveitis
Number of subjects: 350
Study 21207237 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 4 years
Number of subjects: 50
Study 21207237 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HADS score
Number of subjects: 50